KA
NVCR icon

Kovack Advisors’s NovoCure NVCR Stock Holding History

Kovack Advisors’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2,308
Closed -$512K – 735
2021
Q2 		$512K Buy
2,308
+353
+18% +$68.7K 0.06% 349
2021
Q1 		$258K Sell
1,955
-60
-3% -$9.49K 0.03% 516
2020
Q4 		$349K Buy
+2,015
New +$276K 0.05% 361
2020
Q1 		– Sell
-2,768
Closed -$233K – 524
2019
Q4 		$233K Hold
2,768
– – 0.04% 420
2019
Q3 		$207K Buy
+2,768
New +$221K 0.04% 419

Other funds holding NVCR

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Kovack Advisors's NVCR Position: Q3 2021 in Review

Kovack Advisors sold out of NovoCure (NVCR) in Q3 2021, closing a stake of 2,308 shares — an estimated $512K sold.

Kovack Advisors first reported a position in NVCR in Q3 2019 and held it in 5 quarters. The position peaked at $512K in Q2 2021. 317 funds tracked by Wall St. Rank hold NVCR as of Q3 2021.

  • Kovack Advisors reported no remaining NovoCure position as of Q3 2021 after selling out during the quarter.
  • Kovack Advisors sold 2,308 NovoCure shares in Q3 2021, an estimated $512K.
  • Kovack Advisors first reported a position in NovoCure in Q3 2019 and held it in 5 quarters.
  • Kovack Advisors's NovoCure position peaked at $512K in Q2 2021.
  • 317 funds tracked by Wall St. Rank held NovoCure as of Q3 2021.

Based on Kovack Advisors's 13F filing for Q3 2021, filed 3 Nov 2021.